Biotech firm Enveda reports safety success for exercise-mimicking weight-loss pill in Phase 1 trial
Enveda’s experimental tablet ENV-308, designed to replicate exercise-induced appetite suppression, was well tolerated in a Phase 1 study of 88 healthy volunteers.
Enveda announced that its first-in-human trial of ENV-308, a pill intended to harness the appetite-reducing hormone Lac-Phe, demonstrated strong safety across all tested doses in 88 adult volunteers. The molecule, originally identified by Stanford scientists, signals the brain to lower food intake after exercise, but degrades quickly in the bloodstream; the drug aims to extend this effect. While the study did not assess weight loss, participants showed lowered leptin concentrations, especially those with elevated baseline levels.
Animal research indicated that the compound can maintain muscle mass during weight reduction and sustain a leaner physique after treatment stops. Commentators suggested the drug could be used alongside GLP-1 medications, potentially easing dosing frequency and side-effects. Future trials will examine impacts on body weight, composition, and interactions with existing obesity drugs, and the company also plans to explore applications for conditions such as migraines and inflammatory bowel disease.
Why it matters
A safe oral drug that mimics exercise could broaden obesity treatment and reduce reliance on injectable therapies.
In this story
